Search
Summit Therapeutics Inc
SMMTAdd to Watchlist
17.590USD
+0.420+2.45%
Close 10-09 16:00（ET）
14.03BMarket Cap
LossP/E TTM
Summit Therapeutics Inc (SMMT) Stock Price Target & Forecast
Analyst Rating
Based on 18 analysts giving stock ratings to Summit Therapeutics Inc in the past month.
Buy
4 Strong Buy
8 Buy
6 Hold
0 Sell
0 Strong Sell
Target Price
29.921USD+70.10%
SMMT Analyst Recommendation Trends
In the current month, SMMT has received 8 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. SMMT average Analyst price target in the last month is 29.921.
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
4
4
3
3
3
2
3
3
8
8
8
8
10
10
10
10
6
6
5
5
4
4
3
3
0
0
1
1
0
0
0
0
0
0
1
1
1
1
1
1
18
18
18
18
18
17
17
17
SMMT Analyst Rating for Peer Comparison
Updated: Oct 11, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
0
0
27
argenx SE
ARGX
10
13
3
0
0
26
Ionis Pharmaceuticals Inc
IONS
6
14
5
0
0
25
Insmed Inc
INSM
7
18
0
0
0
25
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Revolution Medicines Inc
RVMD
8
14
1
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
IQVIA Holdings Inc
IQV
8
11
3
0
0
22
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Biontech SE
BNTX
4
13
5
0
0
22
Financial Forecasting
Based on analysts' estimates, SMMT EPS is projected to reach -0.290 in FY2026Q3, following reported EPS of -0.277 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.06
-0.18
-0.28
-0.29
-0.36
Actual
-1.44
-0.24
-0.28
--
--
Surprise
-2144.47%
-38.34%
+0.76%
--
--
FAQs
What is Summit Therapeutics Inc's expected revenue for the next quarter?
Summit Therapeutics Inc's expected revenue is 90.91M.
What is Summit Therapeutics Inc's price target?
Analysts forecast that Summit Therapeutics Inc's price target is USD 29.92, with the highest forecast at USD 43.00 and the lowest forecast at USD 11.90.
How have Summit Therapeutics IncSMMT's recent earnings per share performed?
The market expectation was USD -0.28, while Summit Therapeutics IncSMMT's earnings per share (EPS) for the previous quarter was USD -0.24. EPS for the next quarter is expected at USD -0.29.
What is the analyst rating for Summit Therapeutics Inc?
Based on the ratings of Summit Therapeutics Inc's stock from 18 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.